U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H14N2O3S
Molecular Weight 314.359
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VALDECOXIB

SMILES

CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(N)(=O)=O

InChI

InChIKey=LNPDTQAFDNKSHK-UHFFFAOYSA-N
InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)

HIDE SMILES / InChI
Molecular Formula C16H14N2O3S
Molecular Weight 314.359
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:57:42 UTC 2023
Edited
by admin
on Fri Dec 15 15:57:42 UTC 2023
Record UNII
2919279Q3W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VALDECOXIB
EMA EPAR   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
SC-65872
Code English
VALDYN
Brand Name English
VALDECOXIB [MART.]
Common Name English
VALDECOXIB [VANDF]
Common Name English
Valdecoxib [WHO-DD]
Common Name English
VALDECOXIB [MI]
Common Name English
4-(5-METHYL-3-PHENYLISOXAZOL-4-YL)BENZENESULFONAMIDE
Systematic Name English
VALDECOXIB [USAN]
Common Name English
BEXTRA
Brand Name English
VALDECOXIB [HSDB]
Common Name English
valdecoxib [INN]
Common Name English
VALDECOXIB [EMA EPAR]
Common Name English
P-(5-METHYL-3-PHENYL-4-ISOXAZOLYL)BENZENESULFONAMIDE
Common Name English
VALDECOXIB [ORANGE BOOK]
Common Name English
NSC-759846
Code English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS VALDYN (WITHDRAWN: ARTHRITIS, RHEUMATOID)
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
WHO-ATC M01AH03
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
EMA ASSESSMENT REPORTS BEXTRA (WITHDRAWN: DYSMENORRHEA)
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
EMA ASSESSMENT REPORTS VALDYN (WITHDRAWN: DYSMENORRHEA)
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
EMA ASSESSMENT REPORTS BEXTRA (WITHDRAWN: OSTEOARTHRITIS)
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
NCI_THESAURUS C1323
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
EMA ASSESSMENT REPORTS VALDYN (WITHDRAWN: OSTEOARTHRITIS)
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
EMA ASSESSMENT REPORTS BEXTRA (WITHDRAWN: ARTHRITIS, RHEUMATOID)
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
WHO-VATC QM01AH03
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
Code System Code Type Description
DRUG BANK
DB00580
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
PRIMARY
HSDB
7302
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
PRIMARY
MERCK INDEX
m11356
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
PRIMARY Merck Index
DRUG CENTRAL
2799
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
PRIMARY
INN
7815
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
PRIMARY
NCI_THESAURUS
C1869
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
PRIMARY
EVMPD
SUB05065MIG
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
PRIMARY
LACTMED
Valdecoxib
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
PRIMARY
WIKIPEDIA
VALDECOXIB
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
PRIMARY
CHEBI
63634
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
PRIMARY
CAS
181695-72-7
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
PRIMARY
EPA CompTox
DTXSID6044226
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
PRIMARY
USAN
KK-41
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
PRIMARY
ChEMBL
CHEMBL865
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
PRIMARY
NSC
759846
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
PRIMARY
PUBCHEM
119607
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
PRIMARY
RXCUI
278567
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
PRIMARY RxNorm
FDA UNII
2919279Q3W
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
PRIMARY
SMS_ID
100000085238
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
PRIMARY
MESH
C406224
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
PRIMARY
IUPHAR
2894
Created by admin on Fri Dec 15 15:57:42 UTC 2023 , Edited by admin on Fri Dec 15 15:57:42 UTC 2023
PRIMARY
Related Record Type Details
Structure of VALDECOXIB
EXCRETED UNCHANGED
AMOUNT EXCRETED
FECAL; URINE
COX-2
TARGET -> INHIBITOR
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
Plasma protein binding for valdecoxib is about 98% over the concentration range (21-2384 ng/mL).
BINDING
CYTOCHROME P450 2C9
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
CYTOCHROME P450 2C19
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
Structure of 1-HYDROXYVALDECOXIB
METABOLITE ACTIVE -> PARENT
MINOR
URINE
Structure of 1-DEOXY-1-(((4-(5-METHYL-3-PHENYL-4-ISOXAZOLYL)PHENYL)SULFONYL)AMINO)-.BETA.-D-GLUCOPYRANURONIC ACID
METABOLITE -> PARENT
MAJOR
URINE
Structure of .BETA.-D-GLUCOPYRANOSIDURONIC ACID, (4-(4-(AMINOSULFONYL)PHENYL)-3-(3-HYDROXYPHENYL)-5-ISOXAZOLYL)METHYL
METABOLITE -> PARENT
URINE
Structure of PARECOXIB
PRODRUG -> METABOLITE ACTIVE
Structure of 4-(5-METHYL-3-PHENYL-4-ISOXAZOLYL)BENZENESULFONIC ACID
METABOLITE -> PARENT
URINE
Structure of 1-O-(((4-(5-(HYDROXYMETHYL)-3-PHENYL-4-ISOXAZOLYL)PHENYL)SULFONYL)AMINO)-.BETA.-D-GLUCOPYRANURONIC ACID
METABOLITE -> PARENT
URINE
Structure of BENZENESULFONAMIDE, N-HYDROXY-4-(5-(HYDROXYMETHYL)-3-PHENYL-4-ISOXAZOLYL)-
METABOLITE -> PARENT
URINE
Structure of 4-(5-METHYL-3-PHENYL-4-ISOXAZOLYL)BENZENESULFINIC ACID
METABOLITE -> PARENT
URINE
Structure of 1-HYDROXYVALDECOXIB
METABOLITE ACTIVE -> PARENT
Plasma concentrations of valdecoxib were 10-20 fold higher than the corresponding SC-66905 (M1) concentrations. The metabolite M1 is a less potent COX-2 specific inhibitor than the parent.
MAJOR
PLASMA
Structure of BENZENESULFONAMIDE, N-HYDROXY-4-(5-METHYL-3-PHENYL-4-ISOXAZOLYL)-
METABOLITE -> PARENT
MINOR
URINE
Structure of 4-(4-(AMINOSULFONYL)PHENYL)-3-PHENYL-5-ISOXAZOLECARBOXYLIC ACID
METABOLITE -> PARENT
URINE
Structure of 1-O-(((4-(5-METHYL-3-PHENYL-4-ISOXAZOLYL)PHENYL)SULFONYL)AMINO)-.BETA.-D-GLUCOPYRANURONIC ACID
METABOLITE -> PARENT
URINE
Structure of 1-HYDROXYVALDECOXIB
METABOLITE ACTIVE -> PARENT
FECAL
Structure of BENZENESULFONAMIDE, 4-(3-(3-HYDROXYPHENYL)-5-METHYL-4-ISOXAZOLYL)-
METABOLITE -> PARENT
URINE
Structure of 4-(2-AMINO-1-HYDROXY-2-PHENYLETHYL)BENZENESULFONAMIDE
METABOLITE -> PARENT
URINE
Structure of (4-(4-(AMINOSULFONYL)PHENYL)-3-PHENYL-5-ISOXAZOLYL)METHYL .BETA.-D-GLUCOPYRANOSIDURONIC ACID
METABOLITE -> PARENT
MAJOR
URINE
Related Record Type Details
Structure of VALDECOXIB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
ORAL BIOAVAILABILITY PHARMACOKINETIC ORAL ADMINISTRATION

Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966